RICOVIR EM 300mg/200mg tablet

• Treatment of HIV infection

RICOVIR EM 300mg/200mg tablet   is a strong anti-HIV medicine that may show certain adverse while manageable impact on the body during the treatment. As these effects resolve on their own without any special medical attention. However, if you ever experience serious or unusual side effects contact your healthcare professional immediately.

Some common side effects include:

• Nausea
• Diarrhea
• Headache
• Depression
• Rash
• Dizziness
• Fatigue
• Vomiting
• Insomnia (difficulty sleeping)
• Weakness
• Abnormal dreams
• Abdominal pain
• Weight loss

• The dosage and duration of the RICOVIR EM 300mg/200mg tablet are decided by the doctor based on the severity of the infection and other health factors. This tablet can be taken with or without food but take it at the same time everyday for better results.
• Before starting this medicine, please inform your doctor about your medical history. If you experience any signs and symptoms while eating this medication that are not manageable, do not ignore those symptoms because they may lead to a higher risk.​​
  

• The dosage and duration of the RICOVIR EM 300mg/200mg tablet are decided by the doctor based on the severity of the infection and other health factors. This tablet can be taken with or without food but take it at the same time everyday for better results.
• Before starting this medicine, please inform your doctor about your medical history. If you experience any signs and symptoms while eating this medication that are not manageable, do not ignore those symptoms because they may lead to a higher risk.

• Ogbuagu, O., Ruane, P. J., Podzamczer, D., Salazar, L. C., Henry, K., Asmuth, D. M., ... & Young, B. (2021). Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial. The lancet HIV, 8(7), e397-e407. https://pubmed.ncbi.nlm.nih.gov/34197772/
• Gallant, J. E., Daar, E. S., Raffi, F., Brinson, C., Ruane, P., DeJesus, E., ... & Rhee, M. S. (2016). Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial. The lancet HIV, 3(4), e158-e165. https://pubmed.ncbi.nlm.nih.gov/27036991/
• Mayer, K. H., Molina, J. M., Thompson, M. A., Anderson, P. L., Mounzer, K. C., De Wet, J. J., ... & Hare, C. B. (2020). Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. The Lancet, 396(10246), 239-254. https://pubmed.ncbi.nlm.nih.gov/32711800/
• Plosker, G. L. (2013). Emtricitabine/tenofovir disoproxil fumarate: a review of its use in HIV-1 pre-exposure prophylaxis. Drugs, 73(3), 279-291. https://pubmed.ncbi.nlm.nih.gov/29584848/
• Liaw, Y. F., Sheen, I. S., Lee, C. M., Akarca, U. S., Papatheodoridis, G. V., Suet‐Hing Wong, F., ... & Schiff, E. R. (2011). Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology, 53(1), 62-72. https://pubmed.ncbi.nlm.nih.gov/21254162/
• Dando, T. M., & Wagstaff, A. J. (2004). Emtricitabine/tenofovir disoproxil fumarate. Drugs, 64(18), 2075-2082.